Cardiovascular and subjective central nervous system effects of long-acting local anaesthetics in man.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 495929)

Published in Anaesth Intensive Care on August 01, 1979

Authors

L E Mather, G T Tucker, T M Murphy, M D Stanton-Hicks, J J Bonica

Articles citing this

Status epilepticus following local anesthesia in a previously healthy adult. BMC Res Notes (2016) 0.75

Articles by these authors

Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol (1981) 3.07

Postoperative pain. Br Med J (1978) 2.93

Intrathecal and epidural administration of opioids. Anesthesiology (1984) 2.91

Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72

Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr (1977) 2.43

Pseudomonas colonization in cystic fibrosis. A study of 160 patients. JAMA (1978) 2.42

Amiodarone pharmacokinetics. Am Heart J (1983) 2.42

Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol (1981) 2.38

Immunochemical and enzymatic comparisons of the tryptophan synthase alpha subunits from five species of Enterobacteriaceae. J Bacteriol (1969) 2.29

Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J (2007) 2.16

Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility. Br J Clin Pharmacol (1981) 2.08

Chronic opioids for chronic low back pain--solution or problem? J Am Board Fam Pract (1996) 2.02

The need of a taxonomy. Pain (1979) 1.84

Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity. Anesthesiology (1970) 1.71

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol (1992) 1.71

Polymorphic hydroxylation of debrisoquine. Lancet (1977) 1.69

Plasma concentrations of local anaesthetics after interscalene brachial plexus block. Br J Anaesth (1977) 1.66

Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol (1985) 1.64

Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol (1982) 1.51

Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J (1987) 1.51

Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet (1979) 1.47

Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet (1983) 1.45

Central nervous system toxicity attributable to epidural ropivacaine hydrochloride. Anaesth Intensive Care (1998) 1.42

Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 1.41

The influence of age upon opioid analgesic use in the patient-controlled analgesia (PCA) environment. Anaesthesia (1997) 1.41

Gerontokinetics--a reappraisal. Br J Clin Pharmacol (1992) 1.41

Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol (1980) 1.39

Meperidine kinetics in man. Intravenous injection in surgical patients and volunteers. Clin Pharmacol Ther (1975) 1.39

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol (1997) 1.37

Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther (1988) 1.37

Cardiovascular and central nervous system effects of intravenous levobupivacaine and bupivacaine in sheep. Anesth Analg (1998) 1.35

Measurement of the renal clearance of drugs. Br J Clin Pharmacol (1981) 1.35

Blockade of the pressor response to muscle ischemia by sensory nerve block in man. Am J Physiol (1979) 1.35

Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther (1986) 1.32

Immunochemical comparisons of mutant and wild-type alpha-subunits of tryptophan synthetase. Arch Biochem Biophys (1968) 1.30

Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol (1986) 1.29

Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol (1980) 1.28

Why hypertensive patients vary in their response to oral debrisoquine. Br Med J (1977) 1.25

The prevalence of pain in four cancers. Cancer (1987) 1.25

Solubilization and partial purification of ATPase from a rose cell plasma membrane fraction. Plant Physiol (1984) 1.25

Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica (2006) 1.24

Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos (1997) 1.23

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther (1983) 1.22

A pharmacokinetic approach to postoperative pain: continuous infusion of pethidine. Anaesth Intensive Care (1979) 1.22

Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21

Variables of patient-controlled analgesia. 2. Concurrent infusion. Anaesthesia (1989) 1.21

Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin Pharmacol Ther (1997) 1.21

Pharmacokinetics of fentanyl in lumbar and cervical CSF following lumbar epidural and intravenous administration. Pain (1989) 1.18

Inhibition of protein synthesis in cultured tobacco cells by ultraviolet radiation. Photochem Photobiol (1975) 1.16

The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol (1978) 1.16

Physiopathology and control of postoperative pain. Arch Surg (1977) 1.16

Therapeutic acupuncture in the People's Republic of China implications for American medicine. JAMA (1974) 1.15

Multiple intramuscular injections: a major source of variability in analgesic response to meperidine. Pain (1980) 1.15

Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol (2001) 1.15

Selective spinal analgesia. Lancet (1979) 1.12

Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol (2003) 1.11

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther (1996) 1.11

Lactic acidosis during metformin treatment in an elderly diabetic patient with impaired renal function. Acta Med Scand (1981) 1.11

Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) (2006) 1.10

Pharmacokinetic aspects of intravenous regional anesthesia. Anesthesiology (1971) 1.10

Clinical pharmacokinetics of pethidine. Clin Pharmacokinet (1978) 1.10

Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos (2004) 1.10

Subdural injection of local anesthetic: a complication of epidural anesthesia. Anesthesiology (1985) 1.09

The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg (2000) 1.09

Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther (1982) 1.08

Meperidine and other basic drugs: general method for their determination in plasma. J Pharm Sci (1974) 1.08

Polymorphic metabolism of beta-adrenoceptor antagonists. Br J Clin Pharmacol (1984) 1.08

Routine detection and identification in urine of stimulants and other drugs, some of which may be used to modify performance in sport. J Pharm Pharmacol (1967) 1.08

Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1985) 1.07

Ultraviolet Radiation-stimulated Efflux of 86-Rubidium from Cultured Tobacco Cells. Plant Physiol (1978) 1.07

Studies on absorption of a newly developed enteric-coated erythromycin base. J Clin Pharmacol (1977) 1.06

Requirement for reactive oxygen species in serum-induced and platelet-derived growth factor-induced growth of airway smooth muscle. J Biol Chem (1999) 1.06

Systemic absorption of mepivacaine in commonly used regional block procedures. Anesthesiology (1972) 1.06

Circulatory effects of peridural block. I. Effects of level of analgesia and dose of lidocaine. Anesthesiology (1970) 1.05

Relief of postoperative pain: advances awaiting application. Med J Aust (1989) 1.05

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica (2004) 1.05

Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem (1995) 1.05

Pharmacokinetics of local anaesthetics. Br J Anaesth (1986) 1.04

Pethidine revisited: plasma concentrations and effects after intramuscular injection. Br J Anaesth (1975) 1.04

Journal impact factors: a 'bioequivalence' issue? Br J Clin Pharmacol (2001) 1.04

Pethidine clearance during continuous intravenous infusions in postoperative patients. Br J Clin Pharmacol (1981) 1.04

Relationship between blood meperidine concentrations and analgesic response: a preliminary report. Anesthesiology (1980) 1.04

Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) (2007) 1.04

Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine. Br J Clin Pharmacol (1984) 1.03

Amiodarone pharmacokinetics. Br J Clin Pract Suppl (1986) 1.02

The antitussive effect of dextromethorphan in relation to CYP2D6 activity. Br J Clin Pharmacol (1999) 1.01

Basic principles in managing chronic pain. Arch Surg (1977) 1.01

Management of intractable pain in general practice. GP (1966) 1.01

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet (1986) 1.00

The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol (1997) 1.00

Ventilatory reserve and level of motor block during high spinal and epidural anesthesia. Anesthesiology (1967) 0.99

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing. Br J Clin Pharmacol (1989) 0.99

Acebutolol in hypertension: relationships between drug concentration and effects. Eur J Clin Pharmacol (1978) 0.99

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots. Br J Clin Pharmacol (1989) 0.99

Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J (1997) 0.99

The effect of duration of dose delivery with patient-controlled analgesia on the incidence of nausea and vomiting after hysterectomy. Br J Clin Pharmacol (1998) 0.98